304 related articles for article (PubMed ID: 24259695)
41. Avanafil: a review of its use in patients with erectile dysfunction.
Sanford M
Drugs Aging; 2013 Oct; 30(10):853-62. PubMed ID: 23955441
[TBL] [Abstract][Full Text] [Related]
42. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
[TBL] [Abstract][Full Text] [Related]
43. Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
Wang X; Wang X; Liu T; He Q; Wang Y; Zhang X
PLoS One; 2014; 9(3):e91327. PubMed ID: 24618671
[TBL] [Abstract][Full Text] [Related]
44. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.
Yilmaz D; Bayatli N; Un O; Kadowitz PJ; Sikka SC; Gur S
Urology; 2014 Feb; 83(2):508.e7-12. PubMed ID: 24331245
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of avanafil 200 mg versus sildenafil 100 mg in the treatment of erectile dysfunction after robot-assisted unilateral nerve-sparing prostatectomy: A prospective multicentre study.
Della Camera PA; Tellini R; Cito G; Rastrelli G; Maggi M; Chini T; Nunzio C; Altieri VM; Serni S; Gacci M; Natali A
Urologia; 2020 Feb; 87(1):23-28. PubMed ID: 31441379
[TBL] [Abstract][Full Text] [Related]
47. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Miller MS
Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
[TBL] [Abstract][Full Text] [Related]
48. Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil.
Paduch DA; Bolyakov A; Beardsworth A; Watts SD
BJU Int; 2012 Apr; 109(7):1060-7. PubMed ID: 21883853
[TBL] [Abstract][Full Text] [Related]
49. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale.
Rosen RC; Allen KR; Ni X; Araujo AB
Eur Urol; 2011 Nov; 60(5):1010-6. PubMed ID: 21855209
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of phosphodieterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis.
Jia DD; Shuang WB; Cheng T; Jia XM; Zhang M
Spinal Cord; 2016 Jul; 54(7):494-501. PubMed ID: 26882490
[TBL] [Abstract][Full Text] [Related]
51. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
[TBL] [Abstract][Full Text] [Related]
52. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction.
Ishii N; Nagao K; Fujikawa K; Tachibana T; Iwamoto Y; Kamidono S
Int J Urol; 2006 Aug; 13(8):1066-72. PubMed ID: 16903931
[TBL] [Abstract][Full Text] [Related]
53. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
54. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction.
Salem EA; Kendirci M; Hellstrom WJ
Curr Opin Investig Drugs; 2006 Jul; 7(7):661-9. PubMed ID: 16869121
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
Fanbin L; Mei Y; Yan Z; Yirong Y; Shaoling Z; Yong C; Peng X
Exp Clin Transplant; 2014 Jun; 12(3):184-9. PubMed ID: 24907716
[TBL] [Abstract][Full Text] [Related]
56. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
Hellstrom WJ
Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: A randomized, double blind, multicenter clinical trial.
Kumar M; Pathade AD; Gupta SV; Goyal S; Rath D; Thakre M; Sanmukhani J; Mittal R
Int J Urol; 2022 Apr; 29(4):351-359. PubMed ID: 35080051
[TBL] [Abstract][Full Text] [Related]
58. Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis.
Schmidt HM; Munder T; Gerger H; Frühauf S; Barth J
J Sex Med; 2014 Jun; 11(6):1376-91. PubMed ID: 24641632
[TBL] [Abstract][Full Text] [Related]
59. A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction.
Yuan JQ; Mao C; Yang ZY; Fu XH; Wong SY; Tang JL
Asian J Androl; 2016; 18(1):60-5. PubMed ID: 25966626
[TBL] [Abstract][Full Text] [Related]
60. PDE5 inhibitors: considerations for preference and long-term adherence.
Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
